Get the Stockscreener App
4.69
4.09%
-0.20
After Hours:
4.51
-0.18
-3.84%
Mustang Bio Inc stock is traded at $4.69, with a volume of 90,772.
It is down -4.09% in the last 24 hours and down -49.57% over the past month.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
See More
Previous Close:
$4.89
Open:
$4.65
24h Volume:
90,772
Relative Volume:
0.38
Market Cap:
$6.15M
Revenue:
-
Net Income/Loss:
$-23.42M
P/E Ratio:
-0.0601
EPS:
-78
Net Cash Flow:
$-16.67M
1W Performance:
+14.67%
1M Performance:
-49.57%
6M Performance:
-72.80%
1Y Performance:
-93.35%
1-Day Range:
$4.50
$4.98
1-Week Range:
$3.86
$6.70
52-Week Range:
$3.72
$74.50
Mustang Bio Inc Stock (MBIO) Company Profile
Name
Mustang Bio Inc
Sector
Industry
Phone
(781) 652-4500
Address
377 PLANTATION STREET, WORCESTER, NY
Compare MBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBIO
Mustang Bio Inc
|
4.69 | 6.15M | 0 | -23.42M | -16.67M | -78.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-21 | Initiated | BTIG Research | Buy |
| Oct-02-20 | Initiated | B. Riley FBR | Buy |
| Nov-20-19 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-19 | Initiated | H.C. Wainwright | Buy |
| Jun-21-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Initiated | Oppenheimer | Outperform |
View All
Mustang Bio Inc Stock (MBIO) Latest News
Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga
Mustang Bio stock plunges to 52-week low of $4 - Investing.com
Mustang Bio (MBIO) Stock Price, News & Analysis - MarketBeat
Mustang Bio Inc. Appoints Michael J. Zelefsky as Director -June 13, 2017 at 04:02 pm EDT - Marketscreener.com
Mustang Bio, Inc. Announces Management Changes -April 24, 2017 at 08:00 am EDT - Marketscreener.com
Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer -December 12, 2023 at 06:23 am EST - Marketscreener.com
Mustang Bio, Inc. Terminates Exclusive License Agreement with Regents of the University of California - Marketscreener.com
UBriGene Biosciences Inc. completed the acquisition of Worcester manufacturing facility of Mustang Bio, Inc. - Marketscreener.com
Mustang Bio, Inc. Announces CFO Changes -November 15, 2024 at 04:50 pm EST - Marketscreener.com
Mustang Bio stock plunges to 52-week low of $0.13 By Investing.com - Investing.com Australia
Mustang Bio stock plunges to 52-week low of $0.13 - Investing.com
Mustang Bio Announces Reverse Stock Split - GlobeNewswire
Mustang Bio announces 1-for-50 reverse stock split By Investing.com - Investing.com Nigeria
Dow Gains Over 200 Points; Signet Jewelers Shares Plunge - Benzinga
Mustang Bio Lauds New Stock Split - Baystreet.ca
Mustang Bio announces 1-for-50 reverse stock split - Investing.com India
Mustang Bio secures shareholder nod for major stock issuance By Investing.com - Investing.com Nigeria
Mustang Bio secures shareholder nod for major stock issuance - Investing.com India
Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off - MSN
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
Stock market news: Neumora Therapeutics down by 80.75% while N2OFF surged by 333.47% during mid day trading - Business Upturn
Wall Street Today: US stocks open higher after markets reopen post New Year; Tesla shares down 7% on low delivery data | Stock Market News - Mint
Mustang Bio files to sell 34.77M shares of common stock for holders - MSN
Mustang Bio Inc Still Hasn’t Convinced Analysts? - Stocks Register
Fortress Biotech subsidiary gains FDA approval for cSCC therapy - Investing.com
Likelihood of Approval and Phase Transition Success Rate ModelMB-108 in Recurrent Malignant Glioma - GlobalData
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Mustang Bio faces delisting, appoints new interim CFO - Investing.com
Mustang Bio's Interim CFO Resigns After 10 Months - MarketWatch
Mustang Bio Faces Nasdaq Delisting and Leadership Changes - TipRanks
Mustang Bio, Inc. Announces CFO Changes - Marketscreener.com
ARMISTICE CAPITAL, LLC Acquires New Stake in Mustang Bio Inc - GuruFocus.com
Fortress Biotech Inc. (FBIOP) Quarterly 10-Q Report - Quartzy
Mustang Bio gets extension for Nasdaq compliance By Investing.com - Investing.com South Africa
Crude Oil Brent (F) (QAX25) Quote - The Globe and Mail
Mustang Bio gets extension for Nasdaq compliance - Investing.com
Mustang Bio Receives Positive Listing Determination from Nasdaq - The Manila Times
Mustang Bio Secures Critical Nasdaq Extension, Faces January 2025 Deadline for $1 Compliance | MBIO Stock News - StockTitan
Virus Therapy Gets Orphan Drug Designation for Glioma Treatment - www.oncnursingnews.com/
Mustang Bio Inc (MBIO) Quarterly 10-Q Report - Quartzy
Mustang Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Mustang Bio’s MB-108 receives FDA orphan drug status for glioma treatment - Yahoo Finance
Toll Brothers Inc (TOL-N) QuotePress Release - The Globe and Mail
Mustang Bio gains FDA Orphan Drug Status for glioma treatment - Investing.com India
Mustang Bio Inc Stock (MBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):